drugset / Trial / NCT07814352
A Study of SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal Disease
Phase 1
Recruiting
40 enrolled
Memorial Sloan Kettering Cancer Center
National Comprehensive Cancer Network · collabSyntrix Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether SX-682 in combination with proton craniospinal irradiation (pCSI) is a safe treatment approach for people with melanoma or non-small cell lung cancer (NSCLC) with leptomeningeal disease (LMD). The researchers will also look at whether the treatment combination is effective against participants' cancer.
Timeline
- Start
- 2026-09-04
- Primary completion
- 2029-09
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SX-682 | Small molecule | 200 mg | Oral |